Skip to main content
SpringerLink
Log in

The effectiveness of the anthracycline analog 4′-epidoxorubicin in the treatment of experimental tumors: a review

  • Preclinical Review
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The current report presents the data of the Division of Cancer Treatment of the National Cancer Institute (NCI) on the antitumor activity of the anthracycline antibiotic 4′-epidoxorubicin in experimental tumor systems. Direct comparisons are made with doxorubicin in individual experiments, and the data are related to those of earlier studies in the form of a review of experimental activity, in order to assess the relative activity of 4′-epidoxorubicin and doxorubicin. The experimental test models utilized by the NCI for these studies included the leukemias P388 and L1210, B-16 melanoma, Lewis lung carcinoma, the colon tumors 26 and 38, and the mammary tumors CD8F1 and C3H16/C. The human tumors growing in xenograft in athymic mice included the models LX-1 lung tumor, CX-1 colon tumor, and MX-1 mammary tumor. Additional comparisons were made with the tumor models Gross leukemia, sarcoma 180, MSV-induced sarcoma, MS-2 tumor, and a variety of human tumors growing in athymic mice, as well as with in vivo toxicologic and in vitro cytotoxicity models. Although for 4′-epidoxorubicin there is only a minimal alteration of the configuration of the doxorubicin molecule, quantitative comparison of 4′-epidoxorubicin and doxorubicin revealed not only similarities but also differences in biological activity. Both drugs showed activity against a broad spectrum of experimental tumors, with 4′-epidoxorubicin more effective against some tumors and equally effective against others. 4′-Epidoxorubicin evidenced less toxicity than doxorubicin in both acute and chronic toxicity studies with retention of therapeutic effectiveness and showed reduced cardiotoxicity. With 4′ -epidoxorubicin there resulted a higher therapeutic index and therapeutic ratio, permitting the use of higher dosage and a greater margin of safety. The preclinical differences in therapeutic and toxicologic manifestations of 4′-epidoxorubicin, reflecting apparent alterations in pharmacologic properties and mode of action in comparison with doxorubicin, support the broad spectrum clinical trials of this already-demonstrated clinically active drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. DiMarco A, Gaetani M, Dorigotti L, Soldati M, Bellini O: Studi spermentali sull'attivita antineoplastica del nuovo antibiotico daunomicina. Tumori 49:203–217, 1963

    Google Scholar 

  2. DiMarco A, Gaetani M, Orezzi P, Scarpinato BM, Silvestrini R, Soldati M, Dasdia T, Valentini L: “Daunomycin,” a new antibiotic of the rhodomycin group. Nature 201:706–707, 1964

    Google Scholar 

  3. DiMarco A, Gaetani M, Scarpinato B: Adriamycin (NSC-123, 127): A new antibiotic with antitumor activity. Cancer Chemother Rep 53:33–37, 1969

    Google Scholar 

  4. Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, Spalla C: Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 11:1101, 1969

    Google Scholar 

  5. Sandberg JS, Howsden FL, DiMarco A, Goldin A: Comparison of the antileukemic effect in mice of adriamycin (NSC-123127) with daunomycin (NSC-82151). Cancer Chemother Rep 54:1–7, 1970

    Google Scholar 

  6. Venditti JM, Abbott BJ, DiMarco A, Goldin A: Effectiveness of daunomycin (NSC-82151) against experimental tumors. Cancer Chemother Rep 50:659–665, 1966

    Google Scholar 

  7. DiMarco A, Gaetani M, Dorigotti L, Soldati M, Bellini O: Daunomycin: A new antibiotic with antitumor activity. Cancer Chemother Rep 38:31–38, 1964

    Google Scholar 

  8. DiMarco A, Casazza AM, Dasdia T, Giuliani F, Lenaz L, Necco A, Soranzo C: Cytotoxic, antiviral, and antitumor activity of some derivatives of daunomycin (NSC-82151). Cancer Chemother Rep 57:269–274, 1973

    Google Scholar 

  9. Frei E III, Schabel FM Jr, Goldin A: Comparative chemotherapy of AKR lymphoma and human hematological neoplasia. Cancer Res 34:184–193, 1974

    Google Scholar 

  10. Casazza AM, DiMarco A, DiCuonzo G: Interference of daunomycin and adriamycin on the growth and regression of murine sarcoma virus (Moloney) tumors in mice. Cancer Res 31:1971–1976, 1971

    Google Scholar 

  11. Hoshino A, Kato T, Amo H, Ota K. Antitumor effects of adriamycin on Yoshida rat sarcoma and L1210 mouse leukemia-cross-resistance and combination chemotherapy. In SK Carter, A DiMarco, M Ghione {et al.} (eds): Proceedings of the International Symposium on Adriamycin, Springer-Verlag, New York, 1972, pp 75–89

    Google Scholar 

  12. DiMarco A, Lenaz L, Casazza AM, Scarpinato BM: Activity of adriamycin (NSC-123127) and daunomycin (NSC-82151) against mouse mammary carcinoma. Cancer Chemother Rep 56:153–161, 1972

    Google Scholar 

  13. Goldin A, Johnson RK: Experimental tumor activity of adriamycin (NSC-123127). Cancer Chemother Rep 6:137–145, 1975

    Google Scholar 

  14. Arcamone F, Penco S, Vigevani A, Redaelli S, Franchi S, DiMarco A, Casazza AM, Dasdia T, Formelli F, Necco A, Soranzo C: Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone. J Med Chem 18:703–707, 1975

    Google Scholar 

  15. DiMarco A, Casazza AM, Gambetta R, Supino R, Zunino F: Relationship between activity and amino sugar stereo-chemistry of daunorubicin and adriamycin derivatives. Cancer Res 36:1962–1966, 1976

    Google Scholar 

  16. DiMarco A, Casazza AM, Dasdia T, Necco A, Pratesi G, Rivolta P, Velcich A, Zaccara A, Zunino F: Changes of activity of daunorubicin, adriamycin and stereoisomers following the introduction or removal of hydroxyl groups in the amino sugar moiety. Chem-Biol Interactions 19:291–302, 1977

    Google Scholar 

  17. Arcamone F, DiMarco A, Casazza A: Chemistry and pharmacology of new antitumor anthracyclines. In H Umezawa et al. (eds): Advances in Cancer Chemotherapy, Japan Sci Soc Press Tokyo/Univ Park Press, Baltimore, 1978, pp 297–312

    Google Scholar 

  18. Casazza AM, DiMarco A, Bertazzoli C, Formelli F, Giuliani F, Pratesi G: Antitumor activity, toxicity and pharmacological properties of 4′-epi-adriamycin. In W Siegenthaler, R. Luthy (eds): Current Chemotherapy. Proceedings of the 10th International Congress of Chemotherapy, Zurich, Switzerland Washington, DC, American Society of Microbiology, Vol. 2, 1978, pp 1257–1260

    Google Scholar 

  19. Giuliani F, Bellini O, Casazza AM, Formelli F, Savi G, DiMarco A: Biologic characterization and chemotherapeutic response of MS-2 tumor: A non-regressing mouse sarcoma derived from MSV-M induced sarcoma. Europ J Cancer 14:555–566, 1978

    Google Scholar 

  20. Johnson RK, Chitnis MP, Embrey WM, Gregory EB: In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep 62:1535–1547, 1978

    Google Scholar 

  21. Casazza AM, DiMarco A, Bonadonna G, Bonfante V, Bertazolli C, Bellini O, Pratesi G, Sala L, Ballerini L: Effects of modifications in position 4 of the chromophore or in position 4′ of the aminosugar, on the antitumor activity and toxicity of daunorubicin and doxorubicin. In: ST Crooke, SD Reich (eds): Anthracyclines: Current Status and New Developments New York, Academic Press, 1980, pp 403–430

    Google Scholar 

  22. Giuliani FC, Kaplan NO: New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse. Cancer Res 40:4682–4687, 1980

    Google Scholar 

  23. Giuliani FC, Coirin AK, Rice MR, Kaplan NO: Effect of 4′ -doxorubicin analogs on heterotransplantation of human tumors in congenitally athymic mice. Cancer Treat Rep 65:1063–1075, 1981

    Google Scholar 

  24. Giuliani FC, Zirvi KA, Kaplan NO: Therapeutic response of human tumor xenografts in athymic mice to doxorubicin. Cancer Res 41: 325–335, 1981

    Google Scholar 

  25. Salmon SE, Liu RM, Casazza AM: Evaluation of new anthracycline analogs with the human tumor stem cell assay. Cancer Chemother Pharmacol 6:103–110, 1981

    Google Scholar 

  26. Casazza AM: Antitumor activity of anthracyclines: Experimental studies. In FM Muggia, CW Young, SK Carter (eds): Anthracycline Antibiotics in Cancer Therapy. Developments in Oncology 10, The Hague, Martinus Nijhoff Publishers, 1982, pp 13–29

    Google Scholar 

  27. Arcamone F, Arlandini E, Menozzi M, Valentini L, Vannini E: Doxorubicin and related compounds. I. Physicochemical characterization of the DNA complex. In FM Muggia, CW Young, SK Carter (eds): Anthracycline Antibiotics in Cancer Therapy. Developments in Oncology 10, The Hague, Martinus Nijhoff Publishers, 1982, pp 74–85

    Google Scholar 

  28. Arcamone F, Casazza A, Cassinelli G, DiMarco A, Penco S: Doxorubicin and related compounds. II. Structure- activity considerations. In FM Muggia, CW Young, SK Carter (eds): Anthracycline Antibiotics in Cancer Therapy. Developments in Oncology 10, The Hague, Martinus Nijhoff Publishers, 1982, pp 179–189

    Google Scholar 

  29. Formelli F, Casazza AM: Relationship between tissue distribution and toxicity of new anthracyclines in mice. In P Periti, GG Grassi (eds): Current Chemotherapy and Immunotherapy. Proceedings of the 12th International Congress of Chemotherapy, Florence, Italy, July 1981, Washington, The Amer Soc of Microbiology, Vol.2, 1982, pp 1451–1453

    Google Scholar 

  30. Bertazzolli C, Sammartini U, Tosana MG, Ballerini L, Bellini O: Screening for cardiotoxic properties. In FM Muggia, CW Young, SK Carter (eds): Anthracycline An tibiotics in Cancer Therapy. Developments in Oncology 10, The Hague, Martinus Nijhoff Publishers, 1982, pp 306–316

    Google Scholar 

  31. Bonfante V, Bonadonna G, Villani F, DiFronzo G, Martini A, Casazza AM: Preliminary phase I study of 4′ -epi-adria- mycin. Cancer Treat Rep 63:915–918, 1979

    Google Scholar 

  32. Bonadonna G, Bonfante V: Clinical evaluation of 4′ -epi doxorubicin and 4-demethoxy daunorubicin. In FM Muggia, CW Young, SK Carter (eds): Anthracycline Antibiotics in Cancer Therapy, Developments in Oncology 10, The Hague, Martinus Nijhoff Publishers, 1982, pp 455–465

    Google Scholar 

  33. Young CW, Wittes R, Deesen P, Jones B, Casper E, Warrell R: Clinacal studies of new anthracycline analogs. FM Muggia, CW Young, SK Carter (eds): Anthracycline Antibiotics in Cancer Therapy. Developments in Oncology 10, The Hague, Martinus Nijhoff Publishers, 1982, pp 504–514

    Google Scholar 

  34. Ferrazzi E, Nicoletto O, Vinante O, Maraglino G, Fornasiero P, Pagnin P, Dagnini G, Fiorentino MV: Preliminary phase II experience with 4′-epi-doxorubicin. In FM Muggia, CW Young, SK Carter (eds): Anthracycline Antibiotics in Cancer Therapy, Developments in Oncology 10, The Hague, Martinus Nijhoff Publishers, 1982, pp 562–567

    Google Scholar 

  35. Hurteloup P, Cappelaere P, Armand JP, Mathe G: Phase II clinical evaluation of 4′-epi-doxorubicin. Cancer Treat Rep 67:337–341, 1983

    Google Scholar 

  36. Weenen H, Lankelma J, Penders PGM, McVie JG, Ten Bokkel Huinink WW, de Planque MM, Pinedo HM: Pharmacokinetics of 4′-epi-doxorubicin in man. Investigational New Drugs 1:59–64, 1983

    Google Scholar 

  37. Ganzina F: 4′-Epidoxorubicin, a new analogue of doxorubicin: A preliminary overview of preclinical and clinical data. Cancer Treat Rev 10:1–22, 1983

    Google Scholar 

  38. Villani F, Favalli L, Piccinini F: Relationship between the effect on calcium turnover and early cardiotoxicity of doxorubicin and 4′-epidoxorubicin in guinea pig heart muscle. Tumori 66:689–697, 1980

    Google Scholar 

  39. Caroni P, Villani F, Carafoli E: The cardiotoxic antibiotic doxorubicin inhibits the Na+ /Ca2+ exchange of dog heart sarcolemmal vesicles. FEBS Letters 130:184–186, 1981

    Google Scholar 

  40. Giuliani FC, Spreafico F, Casazza AM: Preclinical studies on new anthracyclines: Antitumor, toxicologic and pharmacologic properties. In HH Hansen (ed): Anthracyclines and Cancer Therapy. Proceedings of a Symposium, Rommeby Brunn, Sweden, Excerpta Medica, Amsterdam, 1983, pp 192–208

    Google Scholar 

  41. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr: Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep 62:1471–1488, 1978

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cancer Treatment, National Cancer Institute, 20205, Bethesda, MD, USA

    Abraham Goldin Ph.D., John M. Venditti & Ruth Geran

Authors
  1. Abraham Goldin Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John M. Venditti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ruth Geran
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldin, A., Venditti, J.M. & Geran, R. The effectiveness of the anthracycline analog 4′-epidoxorubicin in the treatment of experimental tumors: a review. Invest New Drugs 3, 3–21 (1985). https://doi.org/10.1007/BF00176819

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00176819

Key words

Search

Navigation